Highlights Asahi Kasei Corporation

Equities

3407

JP3111200006

Diversified Chemicals

Market Closed - Japan Exchange Other stock markets 06:30:00 06/02/2026 GMT			5-day change	1st Jan Change
1,695.50 ^JPY	+3.38%		+13.07%	+22.07%

02-04	Asahi Kasei Corporation Revises Earnings Guidance for the Full Year Ending March 31, 2026	CI
02-04	Asahi Kasei's Nine-Month Profit Climbs 23%	MT

Highlights

02-04	Asahi Kasei Corporation Revises Earnings Guidance for the Full Year Ending March 31, 2026	CI
02-04	Asahi Kasei's Nine-Month Profit Climbs 23%	MT
02-04	Asahi Kasei Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-30	Diary - Japan corporate earnings week ahead	RE
01-29	Asahi Kasei Develops Pfas-Free Pa66 Offering Low-Friction and High-Load Performance	CI
01-27	Asahi Kasei, Mitsui Chemicals, and Mitsubishi Chemical Enter into Basic Agreement to Promote Decarbonization of Ethylene Production in Western Japan	CI
01-08	Zoll Strengthens Growth Trajectory for Asahi Kasei's Healthcare Sector with U.S. Launch of the Next-Generation Lifevest®? Wcd	CI
01-06	Tranche Update on Asahi Kasei Corporation's Equity Buyback Plan announced on November 5, 2025.	CI
12-05	Asahi Kasei Strengthens Long-Term Profitability by Phasing Out HMD Production as Part of Structural Reform	CI
12-01	Kingswood Capital Management, LP acquired Daramic, LLC from Asahi Kasei Corporation.	CI
12-01	SENSIL by NILIT and ROICA by Asahi Kasei Collaborate to Reduce Apparel?s Footprint	CI
12-01	Asahi Kasei Advance and Teijin Frontier to integrate businesses, effective October 1, 2026	RE
11-30	Teijin Frontier Co., Ltd. concluded a basic agreement to acquire Asahi Kasei Advance Corporation from Asahi Kasei Corporation.	CI
11-12	Asahi Kasei Microdevices Showcases AgeTech and PetTech Solutions Combining Privacy and Convenience At CES 2026	CI
11-10	Calliditas Therapeutics Reports Safety Data for Setanaxib in Patients with Alport Syndrome At the American Society of Nephrology Kidney Week	CI
11-05	Asahi Kasei Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2026	CI
11-05	Asahi Kasei Corporation authorizes a Buyback Plan.	CI
11-05	Asahi Kasei Corporation announces an Equity Buyback for 45,000,000 shares, representing 3.31% for ¥40,000 million.	CI
11-05	Asahi Kasei's Net Income Climbs 10% in Fiscal H1	MT
11-05	Asahi Kasei Corp - to buy back up to 3.31% of shares worth 40 billion yen	RE
11-04	Asahi Kasei Licenses Novel Electrolyte Technology to EAS Batteries for the Market Launch of an Ultra-High-Power Cell	CI
11-04	Asahi Kasei Corp. Announces Nefecon Included in the Updated KDIGO Clinical Practice Guideline, Strengthening Asahi Kasei?s Position in IgA Nephropathy Treatment	CI
23/10/25	Asahi Kasei Expanding Capacity to Manufacture System Components for Clean Hydrogen	CI
21/10/25	Sawai Group Settles Patent Dispute with Asahi Kasei for 4 Billion Yen	MT
14/10/25	Asahi Kasei Corporation agreed to acquire 14.01% stake in R. C. Core Co., Ltd..	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Asahi Kasei Corporation

Equities

3407

JP3111200006

Diversified Chemicals

Highlights

Filters